Pegylated Recombinant Human Hyaluronidase PH20

BIOLOGICAL2 trials

Sponsors

Halozyme Therapeutics, M.D. Anderson Cancer Center

Conditions

Metastatic Pancreatic AdenocarcinomaNon-small Cell Lung CancerStage IV Pancreatic Cancer AJCC v8

Phase 1

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

TerminatedNCT02346370

Halozyme TherapeuticsNon-small Cell Lung Cancer

Start: 2015-02-10End: 2016-11-14Updated: 2019-02-08

Phase 2

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

WithdrawnNCT04058964

M.D. Anderson Cancer CenterMetastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Start: 2020-02-01End: 2022-10-31Updated: 2020-03-13

Related Papers

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

Clinical and Translational Science2021-05-1310 citations

HALO 107-201: A phase Ib, open-label, multicenter study of pegvorhyaluronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC)

Annals of Oncology2018-10-01

Abstract 283: PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances pemetrexed antitumor efficacy in a human nonsquamous NSCLC xenograft model

Cancer Research2016-07-151 citations